Table 2.
Biomarker | Sedentary |
Light |
Moderate |
Vigorous |
||||
---|---|---|---|---|---|---|---|---|
β (SE) | P | β (SE) | P | β (SE) | P | β (SE) | P | |
Aβ42 | −54.12 (21.52) | .014 | 39.47 (22.35) | .081 | 60.74 (22.27) | .008 | 35.42 (23.45) | .135 |
t-tau | −2.89 (15.28) | .850 | 9.88 (15.53) | .526 | −24.31 (15.68) | .125 | −1.79 (16.25) | .913 |
p-tau | −1.45 (1.56) | .356 | 1.57 (1.59) | .327 | −0.46 (1.63) | .779 | −0.11 (1.67) | .947 |
t-tau/Aβ42 | −0.05 (0.03) | .109 | −0.03 (0.03) | .366 | −0.09 (0.03) | .006 | −0.05 (0.04) | .150 |
p-tau/Aβ42 | 0.01 (0.01) | .161 | −0.01 (0.01) | .402 | −0.01 (0.01) | .030 | −0.01 (0.01) | .101 |
NOTE. Models were adjusted for age, sex, APOE ε4 status, interval between CSF collection and accelerometer data, and assay batch. The regression estimate (β) refers to the amount of change in each biomarker for every 1% change in time spent in each PA category. Bolded values refer to associations where P < .05. Italicized values refer to associations where .05 < P < .10.
Abbreviations: CSF, cerebrospinal fluid; β, regression estimate; SE, standard error; Aβ42, amyloid β 42; t-tau, total tau; p-tau, phosphorylated tau; APOE ε4, apolipoprotein E ε4 allele.